Full Fed. Circ. Limits On-Sale Bar’s Reach In Angiomax Case

Law360, New York (July 11, 2016, 11:37 AM EDT) -- The full Federal Circuit ruled Monday that the on-sale bar invalidating a patent is triggered only by a transaction that “bears the general hallmarks of a sale,” holding that The Medicines Co.’s deal with a supplier for experimental batches of the blood thinner Angiomax did not invalidate its patents.

In a unanimous en banc ruling, the full court reached the opposite conclusion from a panel decision last year that held that The Medicines Co.’s transaction was enough to render its patents on methods of making the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.